抗TNF治疗极早期外周型脊柱关节炎的缓解研究:CRESPA研究
CRESPA研究是一项单中心随机对照试验,纳入症状持续时间≤12周的极早期活动性外周型脊柱关节炎(pSpA)患者60例,按2:1随机接受戈利木单抗50mg每4周一次或安慰剂治疗24周。第24周戈利木单抗组临床缓解率显著高于安慰剂组(75% vs 20%,p<0.001),安慰剂组自发缓解率极低。
要点
- 极早期pSpA患者接受戈利木单抗治疗24周临床缓解率达75%,显著优于安慰剂组的20%。
- 安慰剂组自发缓解率仅20%,提示极早期pSpA自然缓解率低。
- 戈利木单抗组需救援治疗者仅10%,安慰剂组为50%,不良事件发生率低且两组相似。
核心结论
- 戈利木单抗在极早期外周型脊柱关节炎中诱导了显著高的临床缓解率,而安慰剂组自发缓解率极低。
研究设计与样本
- CRESPA为单中心随机对照试验,纳入符合ASAS外周型脊柱关节炎分类标准且症状持续时间≤12周的患者,按2:1随机接受戈利木单抗50mg每4周一次或匹配安慰剂治疗24周,共60例。
主要发现
- 第24周戈利木单抗组临床缓解率75%(30/40)显著高于安慰剂组20%(4/20),p<0.001。
- 第12周戈利木单抗组临床缓解率70%(28/40)显著高于安慰剂组15%(3/20),p<0.001。
- 第24周所有次要终点均达到;安慰剂组50%需要救援治疗,戈利木单抗组仅10%。
- 不良事件发生率低且两组相似。
关键数值与推荐
- 主要终点为第24周临床缓解率,临床缓解定义为无关节炎、无附着点炎和无指趾炎。
- 从第12周起,无应答者允许接受戈利木单抗救援治疗。
临床怎么用
- 对于症状持续时间≤12周的极早期活动性外周型脊柱关节炎患者,戈利木单抗可考虑用于快速诱导临床缓解。
局限性
- 本研究为单中心研究,样本量60例,结果需在多中心更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA). METHODS: Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks. The primary end point was the percentage of patients achieving clinical remission at week 24, defined as absence of arthritis, enthesitis and dactylitis. Secondary end points included joint and enthesis counts, patient-reported outcomes, erythrocyte sedimentation rate and C reactive protein. From week 12, non-responders were allowed to receive rescue medication with golimumab. Adverse events were recorded. RESULTS: 60 patients were randomised with similar baseline characteristics. At week 24, a significantly higher percentage of patients receiving golimumab achieved clinical remission compared with placebo (75% (30/40) vs 20% (4/20); p<0.001). At week 12, similar results were observed (70% (28/40) vs 15% (3/20); p<0.001). All secondary end points were met at week 24. Rescue medication was necessary in 50% in the placebo group opposed to only 10% in the golimumab arm. Rates of adverse events were low and similar in both groups. CONCLUSIONS: Markedly high remission induction rates were noted with golimumab in very early pSpA. Of interest, in placebo-treated patients, very low spontaneous remission rates were observed. TRIAL REGISTRATION NUMBER: NCT01426815; Results.
引用
- Carron P, Varkas G, Cypers H, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis. 2017. PMID: 28213565. doi:10.1136/annrheumdis-2016-210775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。